Durability and Decay of Treatment Benefit of Cognitive Behavioral Therapy for Irritable Bowel Syndrome: 12-Month Follow-Up

There is a need for safe and effective IBS treatments that provide immediate and sustained improvement of IBS symptoms, particularly among more severe patients. The aim was to assess long-term clinical response of cognitive behavioral therapy (CBT) with reference to IBS education. A total of 436 Rom...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:The American journal of gastroenterology Jg. 114; H. 2; S. 330 - 338
Hauptverfasser: Lackner, Jeffrey M., Jaccard, James, Radziwon, Christopher D., Firth, Rebecca S., Gudleski, Gregory D., Hamilton, Frank, Katz, Leonard A., Keefer, Laurie, Krasner, Susan S., Ma, Chang-Xing, Sitrin, Michael D., Brenner, Darren M.
Format: Journal Article
Sprache:Englisch
Veröffentlicht: United States Wolters Kluwer Health Medical Research, Lippincott Williams & Wilkins 01.02.2019
Schlagworte:
ISSN:0002-9270, 1572-0241, 1572-0241
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Abstract There is a need for safe and effective IBS treatments that provide immediate and sustained improvement of IBS symptoms, particularly among more severe patients. The aim was to assess long-term clinical response of cognitive behavioral therapy (CBT) with reference to IBS education. A total of 436 Rome III-diagnosed IBS patients (80% F, M age = 41 years) were randomized to: 4 session home-based CBT (minimal contact (MC-CBT)), 10 session clinic-based CBT (standard (S-CBT)), or 4 session IBS education (EDU). Follow-up occurred at 2 weeks and 3, 6, 9, and 12 months following treatment completion. Treatment response was based a priori on the Clinical Global Improvement Scale (global IBS symptom improvement) and IBS Symptom Severity Scale (IBS-SSS). Post-treatment CGI gains were generally maintained by MC-CBT patients at quarterly intervals through 12-month follow-up with negligible decay. For MC-CBT and S-CBT, 39 and 33% of respondents maintained treatment response at every follow-up assessment. The corresponding percent for EDU was 19%, which was significantly lower (p < 0.05) than for the CBT groups. On the IBS-SSS, therapeutic gains also showed a pattern of maintenance with trends towards increased efficacy over time in all conditions, with the mean unit reductions between baseline and follows-up being approximately -76 at immediate and approximately -94 at 12 months (-50 = clinically significant). For treatment-refractory IBS patients, home- and clinic-based CBT resulted in substantial and enduring relief of multiple IBS symptoms that generally extended to 12-month post treatment.
AbstractList BACKGROUND:There is a need for safe and effective IBS treatments that provide immediate and sustained improvement of IBS symptoms, particularly among more severe patients. The aim was to assess long-term clinical response of cognitive behavioral therapy (CBT) with reference to IBS education.METHODS:A total of 436 Rome III-diagnosed IBS patients (80% F, M age = 41 years) were randomized to: 4 session home-based CBT (minimal contact (MC-CBT)), 10 session clinic-based CBT (standard (S-CBT)), or 4 session IBS education (EDU). Follow-up occurred at 2 weeks and 3, 6, 9, and 12 months following treatment completion. Treatment response was based a priori on the Clinical Global Improvement Scale (global IBS symptom improvement) and IBS Symptom Severity Scale (IBS-SSS).RESULTS:Post-treatment CGI gains were generally maintained by MC-CBT patients at quarterly intervals through 12-month follow-up with negligible decay. For MC-CBT and S-CBT, 39 and 33% of respondents maintained treatment response at every follow-up assessment. The corresponding percent for EDU was 19%, which was significantly lower (p < 0.05) than for the CBT groups. On the IBS-SSS, therapeutic gains also showed a pattern of maintenance with trends towards increased efficacy over time in all conditions, with the mean unit reductions between baseline and follows-up being approximately −76 at immediate and approximately −94 at 12 months (−50 = clinically significant).CONCLUSIONS:For treatment-refractory IBS patients, home- and clinic-based CBT resulted in substantial and enduring relief of multiple IBS symptoms that generally extended to 12-month post treatment.
There is a need for safe and effective IBS treatments that provide immediate and sustained improvement of IBS symptoms, particularly among more severe patients. The aim was to assess long-term clinical response of cognitive behavioral therapy (CBT) with reference to IBS education. A total of 436 Rome III-diagnosed IBS patients (80% F, M age = 41 years) were randomized to: 4 session home-based CBT (minimal contact (MC-CBT)), 10 session clinic-based CBT (standard (S-CBT)), or 4 session IBS education (EDU). Follow-up occurred at 2 weeks and 3, 6, 9, and 12 months following treatment completion. Treatment response was based a priori on the Clinical Global Improvement Scale (global IBS symptom improvement) and IBS Symptom Severity Scale (IBS-SSS). Post-treatment CGI gains were generally maintained by MC-CBT patients at quarterly intervals through 12-month follow-up with negligible decay. For MC-CBT and S-CBT, 39 and 33% of respondents maintained treatment response at every follow-up assessment. The corresponding percent for EDU was 19%, which was significantly lower (p < 0.05) than for the CBT groups. On the IBS-SSS, therapeutic gains also showed a pattern of maintenance with trends towards increased efficacy over time in all conditions, with the mean unit reductions between baseline and follows-up being approximately -76 at immediate and approximately -94 at 12 months (-50 = clinically significant). For treatment-refractory IBS patients, home- and clinic-based CBT resulted in substantial and enduring relief of multiple IBS symptoms that generally extended to 12-month post treatment.
There is a need for safe and effective IBS treatments that provide immediate and sustained improvement of IBS symptoms, particularly among more severe patients. The aim was to assess long-term clinical response of cognitive behavioral therapy (CBT) with reference to IBS education.BACKGROUNDThere is a need for safe and effective IBS treatments that provide immediate and sustained improvement of IBS symptoms, particularly among more severe patients. The aim was to assess long-term clinical response of cognitive behavioral therapy (CBT) with reference to IBS education.A total of 436 Rome III-diagnosed IBS patients (80% F, M age = 41 years) were randomized to: 4 session home-based CBT (minimal contact (MC-CBT)), 10 session clinic-based CBT (standard (S-CBT)), or 4 session IBS education (EDU). Follow-up occurred at 2 weeks and 3, 6, 9, and 12 months following treatment completion. Treatment response was based a priori on the Clinical Global Improvement Scale (global IBS symptom improvement) and IBS Symptom Severity Scale (IBS-SSS).METHODSA total of 436 Rome III-diagnosed IBS patients (80% F, M age = 41 years) were randomized to: 4 session home-based CBT (minimal contact (MC-CBT)), 10 session clinic-based CBT (standard (S-CBT)), or 4 session IBS education (EDU). Follow-up occurred at 2 weeks and 3, 6, 9, and 12 months following treatment completion. Treatment response was based a priori on the Clinical Global Improvement Scale (global IBS symptom improvement) and IBS Symptom Severity Scale (IBS-SSS).Post-treatment CGI gains were generally maintained by MC-CBT patients at quarterly intervals through 12-month follow-up with negligible decay. For MC-CBT and S-CBT, 39 and 33% of respondents maintained treatment response at every follow-up assessment. The corresponding percent for EDU was 19%, which was significantly lower (p < 0.05) than for the CBT groups. On the IBS-SSS, therapeutic gains also showed a pattern of maintenance with trends towards increased efficacy over time in all conditions, with the mean unit reductions between baseline and follows-up being approximately -76 at immediate and approximately -94 at 12 months (-50 = clinically significant).RESULTSPost-treatment CGI gains were generally maintained by MC-CBT patients at quarterly intervals through 12-month follow-up with negligible decay. For MC-CBT and S-CBT, 39 and 33% of respondents maintained treatment response at every follow-up assessment. The corresponding percent for EDU was 19%, which was significantly lower (p < 0.05) than for the CBT groups. On the IBS-SSS, therapeutic gains also showed a pattern of maintenance with trends towards increased efficacy over time in all conditions, with the mean unit reductions between baseline and follows-up being approximately -76 at immediate and approximately -94 at 12 months (-50 = clinically significant).For treatment-refractory IBS patients, home- and clinic-based CBT resulted in substantial and enduring relief of multiple IBS symptoms that generally extended to 12-month post treatment.CONCLUSIONSFor treatment-refractory IBS patients, home- and clinic-based CBT resulted in substantial and enduring relief of multiple IBS symptoms that generally extended to 12-month post treatment.
Author Hamilton, Frank
Jaccard, James
Katz, Leonard A.
Firth, Rebecca S.
Krasner, Susan S.
Sitrin, Michael D.
Keefer, Laurie
Lackner, Jeffrey M.
Brenner, Darren M.
Gudleski, Gregory D.
Radziwon, Christopher D.
Ma, Chang-Xing
AuthorAffiliation 6 Department of Biostatistics, University at Buffalo SUNY, Buffalo, NY, USA
1 Department of Medicine, Jacobs School of Medicine, Divisions of Behavioral Medicine and Gastroenterology, University at Buffalo, Buffalo, NY, USA
3 Division of Digestive Disease and Nutrition, NIDDK, Bethesda, MD, USA
4 Department of Medicine, Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, New York, NY, USA
5 Departments of Anesthesiology, Jacobs School of Medicine, University at Buffalo, Buffalo, NY, USA
2 School of Social Work, New York University,New York, NY,USA
7 Department of Medicine, Feinberg School of Medicine, Division of Gastroenterology, Northwestern University, Chicago, IL, USA
AuthorAffiliation_xml – name: 1 Department of Medicine, Jacobs School of Medicine, Divisions of Behavioral Medicine and Gastroenterology, University at Buffalo, Buffalo, NY, USA
– name: 7 Department of Medicine, Feinberg School of Medicine, Division of Gastroenterology, Northwestern University, Chicago, IL, USA
– name: 4 Department of Medicine, Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, New York, NY, USA
– name: 3 Division of Digestive Disease and Nutrition, NIDDK, Bethesda, MD, USA
– name: 2 School of Social Work, New York University,New York, NY,USA
– name: 5 Departments of Anesthesiology, Jacobs School of Medicine, University at Buffalo, Buffalo, NY, USA
– name: 6 Department of Biostatistics, University at Buffalo SUNY, Buffalo, NY, USA
Author_xml – sequence: 1
  givenname: Jeffrey M.
  surname: Lackner
  fullname: Lackner, Jeffrey M.
  organization: Department of Medicine, Jacobs School of Medicine, Divisions of Behavioral Medicine and Gastroenterology, University at Buffalo, Buffalo, NY, USA
– sequence: 2
  givenname: James
  surname: Jaccard
  fullname: Jaccard, James
  organization: School of Social Work, New York University, New York, NY, USA
– sequence: 3
  givenname: Christopher D.
  surname: Radziwon
  fullname: Radziwon, Christopher D.
  organization: Department of Medicine, Jacobs School of Medicine, Divisions of Behavioral Medicine and Gastroenterology, University at Buffalo, Buffalo, NY, USA
– sequence: 4
  givenname: Rebecca S.
  surname: Firth
  fullname: Firth, Rebecca S.
  organization: Department of Medicine, Jacobs School of Medicine, Divisions of Behavioral Medicine and Gastroenterology, University at Buffalo, Buffalo, NY, USA
– sequence: 5
  givenname: Gregory D.
  surname: Gudleski
  fullname: Gudleski, Gregory D.
  organization: Department of Medicine, Jacobs School of Medicine, Divisions of Behavioral Medicine and Gastroenterology, University at Buffalo, Buffalo, NY, USA
– sequence: 6
  givenname: Frank
  surname: Hamilton
  fullname: Hamilton, Frank
  organization: Division of Digestive Disease and Nutrition, NIDDK, Bethesda, MD, USA
– sequence: 7
  givenname: Leonard A.
  surname: Katz
  fullname: Katz, Leonard A.
  organization: Department of Medicine, Jacobs School of Medicine, Divisions of Behavioral Medicine and Gastroenterology, University at Buffalo, Buffalo, NY, USA
– sequence: 8
  givenname: Laurie
  surname: Keefer
  fullname: Keefer, Laurie
  organization: Department of Medicine, Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, New York, NY, USA
– sequence: 9
  givenname: Susan S.
  surname: Krasner
  fullname: Krasner, Susan S.
  organization: Department of Medicine, Jacobs School of Medicine, Divisions of Behavioral Medicine and Gastroenterology, University at Buffalo, Buffalo, NY, USA;, Departments of Anesthesiology, Jacobs School of Medicine, University at Buffalo, Buffalo, NY, USA
– sequence: 10
  givenname: Chang-Xing
  surname: Ma
  fullname: Ma, Chang-Xing
  organization: Department of Biostatistics, University at Buffalo SUNY, Buffalo, NY, USA
– sequence: 11
  givenname: Michael D.
  surname: Sitrin
  fullname: Sitrin, Michael D.
  organization: Department of Medicine, Jacobs School of Medicine, Divisions of Behavioral Medicine and Gastroenterology, University at Buffalo, Buffalo, NY, USA
– sequence: 12
  givenname: Darren M.
  surname: Brenner
  fullname: Brenner, Darren M.
  organization: Department of Medicine, Feinberg School of Medicine, Division of Gastroenterology, Northwestern University, Chicago, IL, USA
BackLink https://www.ncbi.nlm.nih.gov/pubmed/30429592$$D View this record in MEDLINE/PubMed
BookMark eNp1UstuFDEQtFAQ2Sx8ABdkiQsXgx_jeXBAgk0CkYI4sDlb9kxP1pHHXjyeTYavj1ebIIjEqaV2dbmqu07QkQ8eEHrN6HtGRf1hLJhoJKGsJlQ0Jbl7hhZMVpxQXrAjtKCUctLwih6jk3G8oZRJXskX6FjQgjey4Qv0-3SK2lhn04y17_AptHrGocfrCDoN4BP-Ah56m_bNVbj2Ntkd5OZG72yI2uH1BqLezrgPEV_EaJM2LgPCLTj8c_ZdDAN8xIyT78GnDT4PzoVbcrV9iZ732o3w6qEu0dX52Xr1jVz--Hqx-nxJ2qIRiYhKVMBLnY0VRrKiaUFqKeu2pF0nKGuEYXVhOsN4L0sA05fGiJoWYAyTUIol-nTg3U5mgK7NnrJstY120HFWQVv174u3G3UddqrMP-eFZYJ3DwQx_JpgTGqwYwvOaQ9hGhVnQtQ866QZ-vYJ9CZM0Wd7SvBCMM6aXJbozd-K_kh5PEsGVAdAG8M4RuhVm9eabNgLtE4xqvYBUIcAqBwAtQ-AusuT7MnkI_n_Z-4BxA2ztw
CitedBy_id crossref_primary_10_1007_s11894_019_0683_8
crossref_primary_10_1016_j_cgh_2023_09_013
crossref_primary_10_1097_YCO_0000000000000628
crossref_primary_10_7759_cureus_54138
crossref_primary_10_1186_s40695_021_00064_5
crossref_primary_10_1146_annurev_med_042320_014032
crossref_primary_10_1001_jama_2020_22532
crossref_primary_10_1007_s11894_024_00940_w
crossref_primary_10_1053_j_gastro_2020_09_041
crossref_primary_10_1186_s13030_021_00226_x
crossref_primary_10_1016_j_cgh_2021_12_005
crossref_primary_10_3748_wjg_v29_i26_4120
crossref_primary_10_1097_MPG_0000000000003286
crossref_primary_10_1016_j_brat_2022_104063
crossref_primary_10_1097_JU_0000000000003847
crossref_primary_10_1093_tbm_ibz166
crossref_primary_10_1016_S2468_1253_19_30291_2
crossref_primary_10_1093_abm_kaaa119
crossref_primary_10_1136_gutjnl_2019_318583
crossref_primary_10_1007_s11894_020_00769_z
crossref_primary_10_14309_ajg_0000000000001036
crossref_primary_10_14309_ajg_0000000000000502
crossref_primary_10_1001_jama_2021_6758
crossref_primary_10_1038_s41392_023_01673_4
crossref_primary_10_1016_j_jpsychores_2021_110481
crossref_primary_10_1016_j_pop_2023_03_010
crossref_primary_10_1038_s41572_020_00222_5
crossref_primary_10_1111_nmo_14602
crossref_primary_10_1080_15332985_2023_2186736
crossref_primary_10_3389_fpubh_2022_947097
crossref_primary_10_1007_s12671_024_02435_1
crossref_primary_10_1186_s40168_021_01188_6
crossref_primary_10_1136_gutjnl_2021_324598
crossref_primary_10_1080_17474124_2020_1780118
crossref_primary_10_1016_j_gastha_2023_10_003
crossref_primary_10_1038_s41467_023_39058_4
crossref_primary_10_1097_j_pain_0000000000003186
crossref_primary_10_1136_flgastro_2024_103012
crossref_primary_10_3390_gastroent15030056
crossref_primary_10_1053_j_gastro_2021_09_015
crossref_primary_10_1016_j_neubiorev_2021_12_020
Cites_doi 10.1001/jama.285.17.2208
10.1038/nrdp.2016.14
10.1097/MEG.0b013e3283333b61
10.1016/j.cgh.2013.03.011
10.1038/ajg.2011.139
10.1056/NEJMra1607547
10.1053/j.gastro.2005.11.058
10.1186/1471-2288-9-57
10.1177/0962280206074463
10.1016/j.cct.2012.07.013
10.1038/ajg.2014.187
10.1016/j.amjmed.2011.08.026
10.1016/j.cgh.2011.06.014
10.1016/j.cgh.2008.03.004
10.1046/j.1365-2036.1997.142318000.x
10.1016/j.cgh.2010.02.007
10.1111/j.1572-0241.2004.30509.x
10.1136/bmj.38545.505764.06
10.1053/j.gastro.2018.03.063
ContentType Journal Article
Copyright Written work prepared by employees of the Federal Government as part of their official duties is, under the U.S. Copyright Act, a “work of the United States Government” for which copyright protection under Title 17 of the United States Code is not available. As such, copyright does not extend to the contributions of employees of the Federal Government.
Copyright_xml – notice: Written work prepared by employees of the Federal Government as part of their official duties is, under the U.S. Copyright Act, a “work of the United States Government” for which copyright protection under Title 17 of the United States Code is not available. As such, copyright does not extend to the contributions of employees of the Federal Government.
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
3V.
7X7
7XB
88E
8FI
8FJ
8FK
ABUWG
AFKRA
BENPR
CCPQU
FYUFA
GHDGH
K9.
M0S
M1P
PHGZM
PHGZT
PJZUB
PKEHL
PPXIY
PQEST
PQQKQ
PQUKI
PRINS
7X8
5PM
DOI 10.1038/s41395-018-0396-x
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
ProQuest Central (Corporate)
Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
Medical Database (Alumni Edition)
Hospital Premium Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central (Alumni)
ProQuest Central UK/Ireland
ProQuest Central
ProQuest One
Health Research Premium Collection
Health Research Premium Collection (Alumni)
ProQuest Health & Medical Complete (Alumni)
ProQuest Health & Medical Collection
Medical Database
ProQuest Central Premium
ProQuest One Academic (New)
ProQuest Health & Medical Research Collection
ProQuest One Academic Middle East (New)
ProQuest One Health & Nursing
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Academic (retired)
ProQuest One Academic UKI Edition
ProQuest Central China
MEDLINE - Academic
PubMed Central (Full Participant titles)
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
ProQuest One Academic Middle East (New)
ProQuest One Academic Eastern Edition
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
ProQuest One Community College
ProQuest One Health & Nursing
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
ProQuest Central China
ProQuest Hospital Collection (Alumni)
ProQuest Central
ProQuest Health & Medical Complete
ProQuest Health & Medical Research Collection
Health Research Premium Collection
ProQuest Medical Library
ProQuest One Academic UKI Edition
Health and Medicine Complete (Alumni Edition)
Health & Medical Research Collection
ProQuest Central (New)
ProQuest One Academic
ProQuest One Academic (New)
ProQuest Medical Library (Alumni)
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList ProQuest One Academic Middle East (New)
MEDLINE
MEDLINE - Academic
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: BENPR
  name: ProQuest Central
  url: https://www.proquest.com/central
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
Education
EISSN 1572-0241
EndPage 338
ExternalDocumentID PMC6737527
30429592
10_1038_s41395_018_0396_x
Genre Randomized Controlled Trial
Journal Article
Research Support, N.I.H., Extramural
GrantInformation_xml – fundername: NIDDK NIH HHS
  grantid: U01 DK077738
GroupedDBID ---
-Q-
0R~
123
23M
36B
39C
4.4
53G
5RE
6J9
70F
7X7
8FI
8GM
AAAAV
AAGIX
AAHPQ
AAIQE
AAJCS
AAMOA
AAQKA
AAQQT
AASCR
AASXQ
AAYXX
ABASU
ABDIG
ABJNI
ABLJU
ABOCM
ABPXF
ABUWG
ABVCZ
ABXYN
ABZZY
ACBKD
ACGFO
ACGFS
ACILI
ACKTT
ACLDA
ACNWC
ACOAL
ACXJB
ACZKN
ADBBV
ADFRT
ADGGA
ADHPY
ADKSD
ADSXY
AEBDS
AEETU
AENEX
AEXYK
AFBFQ
AFDTB
AFEBI
AFEXH
AFKRA
AFNMH
AFUWQ
AGAYW
AHMBA
AHOMT
AHQNM
AHQVU
AHSBF
AHVBC
AINUH
AJCLO
AJIOK
AJNWD
AJRNO
AJZMW
AKCTQ
AKRWK
AKULP
ALKUP
ALMA_UNASSIGNED_HOLDINGS
ALMTX
AMJPA
AMKUR
AMNEI
AOHHW
AOQMC
BENPR
BPHCQ
BVXVI
BYPQX
C45
CITATION
CS3
DIWNM
EBS
EE.
EEVPB
EJD
EMB
ERAAH
F5P
FCALG
FDB
FDQFY
FYUFA
GNXGY
GQDEL
HLJTE
HZ~
IHE
IKREB
IKYAY
JSO
M1P
O9-
ODMTH
OPUJH
OVD
OVDNE
P0W
P2P
PQQKQ
PROAC
PSQYO
RLZ
RNT
RNTTT
SJN
SV3
TEORI
TSPGW
UKHRP
XIF
--K
.55
.GJ
1B1
1OC
31~
3O-
4G.
5VS
88E
8FJ
AAEDT
AALRI
AAQFI
AAQXK
AAXUO
AAYOK
ABAWZ
ABWVN
ACIJW
ACRPL
ACXQS
ADMUD
ADNKB
ADNMO
AFBPY
AFFNX
AI.
AJAOE
ALIPV
CAG
CCPQU
CGR
COF
CUY
CVF
ECM
EIF
EMOBN
FEDTE
FGOYB
HMCUK
HVGLF
IPNFZ
LH4
LW6
M41
N4W
NPM
NQ-
PHGZT
R2-
RIG
ROL
RPZ
SEW
SSZ
UDS
VH1
X7M
XPP
ZGI
ZXP
ZZMQN
3V.
7XB
8FK
AFFHD
K9.
PHGZM
PJZUB
PKEHL
PPXIY
PQEST
PQUKI
PRINS
7X8
5PM
ID FETCH-LOGICAL-c493t-3737e26a1574b5149ce5a558c60dd30193b184bdb12f56eebf6bb3804ebb15e63
IEDL.DBID BENPR
ISICitedReferencesCount 44
ISICitedReferencesURI http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000463158000024&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN 0002-9270
1572-0241
IngestDate Tue Nov 04 01:46:12 EST 2025
Mon Sep 08 12:38:40 EDT 2025
Fri Nov 07 08:35:10 EST 2025
Thu Apr 03 06:56:32 EDT 2025
Sat Nov 29 07:49:53 EST 2025
Tue Nov 18 21:20:02 EST 2025
IsDoiOpenAccess false
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 2
Language English
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c493t-3737e26a1574b5149ce5a558c60dd30193b184bdb12f56eebf6bb3804ebb15e63
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ObjectType-Undefined-3
Specific author contributions: JL and JJ had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. Study concept and design: JL, RF, JJ, GDG, LAK, SSK, LK, DB, MDS, and FH; acquisition, analysis, or interpretation of data: all authors; drafting of the manuscript: JL and JJ; critical revision of the manuscript for important intellectual content: all authors; statistical analysis: JJ; obtained funding: JL, JJ, RF, LK, and MDS: administrative, technical, or material support: all authors; study supervision: JL, RF, JJ, LK, DB, FH, and C-XM.
OpenAccessLink https://www.ncbi.nlm.nih.gov/pmc/articles/6737527
PMID 30429592
PQID 3243121924
PQPubID 2041977
PageCount 9
ParticipantIDs pubmedcentral_primary_oai_pubmedcentral_nih_gov_6737527
proquest_miscellaneous_2133823730
proquest_journals_3243121924
pubmed_primary_30429592
crossref_citationtrail_10_1038_s41395_018_0396_x
crossref_primary_10_1038_s41395_018_0396_x
PublicationCentury 2000
PublicationDate 2019-02-01
PublicationDateYYYYMMDD 2019-02-01
PublicationDate_xml – month: 02
  year: 2019
  text: 2019-02-01
  day: 01
PublicationDecade 2010
PublicationPlace United States
PublicationPlace_xml – name: United States
– name: New York
PublicationTitle The American journal of gastroenterology
PublicationTitleAlternate Am J Gastroenterol
PublicationYear 2019
Publisher Wolters Kluwer Health Medical Research, Lippincott Williams & Wilkins
Publisher_xml – name: Wolters Kluwer Health Medical Research, Lippincott Williams & Wilkins
References Lackner (R26-20250611) 2011; 9
Ford (R8-20250611) 2017; 376
Lackner (R10-20250611) 2008; 6
Irvine (R15-20250611) 2006; 130
Sheehan (R31-20250611) 1998; 59
Marshall (R21-20250611) 2009; 9
Holroyd (R29-20250611) 2001; 285
Shah (R1-20250611) 2012; 125
Lackner (R28-20250611) 2010; 8
Ljótsson (R6-20250611) 2011; 106
Francis (R17-20250611) 1997; 11
Lackner (R32-20250611) 2013; 11
Lackner (R5-20250611) 2018; 155
Wilson (R25-20250611) 1999; 6
Lackner (R4-20250611) 2012; 33
Ringstrom (R13-20250611) 2010; 22
Chey (R2-20250611) 2004; 99
Enck (R3-20250611) 2016; 2
Kennedy (R7-20250611) 2005; 331
van Buuren (R23-20250611) 2007; 16
Ford (R14-20250611) 2014; 109
31614122 - Gastroenterology. 2019 Dec;157(6):1684-1686
References_xml – volume: 285
  start-page: 2208
  year: 2001
  ident: R29-20250611
  article-title: Management of chronic tension-type headache with tricyclic antidepressant medication, stress management therapy, and their combination: a randomized controlled trial [see comment]
  publication-title: JAMA
  doi: 10.1001/jama.285.17.2208
– volume: 2
  start-page: 16014
  year: 2016
  ident: R3-20250611
  article-title: Irritable bowel syndrome
  publication-title: Nat Rev Dis Prim
  doi: 10.1038/nrdp.2016.14
– volume: 22
  start-page: 420
  year: 2010
  ident: R13-20250611
  article-title: Structured patient education is superior to written information in the management of patients with irritable bowel syndrome: a randomized controlled study
  publication-title: Eur J Gastroenterol Hepatol
  doi: 10.1097/MEG.0b013e3283333b61
– volume: 11
  start-page: 1147
  year: 2013
  ident: R32-20250611
  article-title: Type, rather than number, of mental and physical comorbidities increases the severity of symptoms in patients with irritable bowel syndrome
  publication-title: Clin Gastroenterol Hepatol
  doi: 10.1016/j.cgh.2013.03.011
– volume: 6
  start-page: 289
  year: 1999
  ident: R25-20250611
  article-title: Rapid response to cognitive behavior therapy
  publication-title: Clin Psychol: Sci Pract.
– volume: 106
  start-page: 1481
  year: 2011
  ident: R6-20250611
  article-title: Internet-delivered exposure-based treatment vs. stress management for irritable bowel syndrome: a randomized trial
  publication-title: Am J Gastroenterol
  doi: 10.1038/ajg.2011.139
– volume: 376
  start-page: 2566
  year: 2017
  ident: R8-20250611
  article-title: Irritable bowel syndrome
  publication-title: N Engl J Med
  doi: 10.1056/NEJMra1607547
– volume: 130
  start-page: 1538
  year: 2006
  ident: R15-20250611
  article-title: Design of treatment trials for functional gastrointestinal disorders
  publication-title: Gastroenterology
  doi: 10.1053/j.gastro.2005.11.058
– volume: 9
  start-page: 57
  year: 2009
  ident: R21-20250611
  article-title: Combining estimates of interest in prognostic modelling studies after multiple imputation: current practice and guidelines
  publication-title: BMC Med Res Methodol
  doi: 10.1186/1471-2288-9-57
– volume: 16
  start-page: 219
  year: 2007
  ident: R23-20250611
  article-title: Multiple imputation of discrete and continuous data by fully conditional specification
  publication-title: Stat Methods Med Res
  doi: 10.1177/0962280206074463
– volume: 33
  start-page: 1293
  year: 2012
  ident: R4-20250611
  article-title: The Irritable Bowel Syndrome Outcome Study (IBSOS): rationale and design of a randomized, placebo-controlled trial with 12 month follow up of self- versus clinician-administered CBT for moderate to severe irritable bowel syndrome
  publication-title: Contemp Clin Trials
  doi: 10.1016/j.cct.2012.07.013
– volume: 109
  start-page: S2
  year: 2014
  ident: R14-20250611
  article-title: American College of Gastroenterology monograph on the management of irritable bowel syndrome and chronic idiopathic constipation
  publication-title: Am J Gastroenterol
  doi: 10.1038/ajg.2014.187
– volume: 125
  start-page: 381
  year: 2012
  ident: R1-20250611
  article-title: Evaluation of harm in the pharmacotherapy of irritable bowel syndrome
  publication-title: Am J Med
  doi: 10.1016/j.amjmed.2011.08.026
– volume: 9
  start-page: 957
  year: 2011
  ident: R26-20250611
  article-title: Patient-reported outcomes for irritable bowel syndrome are associated with patients’ severity ratings of gastrointestinal symptoms and psychological factors
  publication-title: Clin Gastroenterol Hepatol
  doi: 10.1016/j.cgh.2011.06.014
– volume: 6
  start-page: 899
  year: 2008
  ident: R10-20250611
  article-title: Self-administered cognitive behavior therapy for moderate to severe irritable bowel syndrome: clinical efficacy, tolerability, feasibility
  publication-title: Clin Gastroenterol Hepatol
  doi: 10.1016/j.cgh.2008.03.004
– volume: 11
  start-page: 395
  year: 1997
  ident: R17-20250611
  article-title: The irritable bowel severity scoring system: a simple method of monitoring irritable bowel syndrome and its progress
  publication-title: Aliment Pharmacol Ther
  doi: 10.1046/j.1365-2036.1997.142318000.x
– volume: 8
  start-page: 426
  year: 2010
  ident: R28-20250611
  article-title: Rapid response to cognitive behavior therapy predicts treatment outcome in patients with irritable bowel syndrome
  publication-title: Clin Gastroenterol Hepatol
  doi: 10.1016/j.cgh.2010.02.007
– volume: 59
  start-page: 22
  issue: Suppl 20
  year: 1998
  ident: R31-20250611
  article-title: The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10
  publication-title: J Clin Psychiatry
– volume: 99
  start-page: 2195
  year: 2004
  ident: R2-20250611
  article-title: Long-term safety and efficacy of alosetron in women with severe diarrhea-predominant irritable bowel syndrome
  publication-title: Am J Gastroenterol
  doi: 10.1111/j.1572-0241.2004.30509.x
– volume: 331
  start-page: 435
  year: 2005
  ident: R7-20250611
  article-title: Cognitive behaviour therapy in addition to antispasmodic treatment for irritable bowel syndrome in primary care: randomised controlled trial
  publication-title: Br Med J
  doi: 10.1136/bmj.38545.505764.06
– volume: 155
  start-page: 47
  year: 2018
  ident: R5-20250611
  article-title: Improvement in gastrointestinal symptoms after cognitive behavior therapy for refractory irritable bowel syndrome
  publication-title: Gastroenterology
  doi: 10.1053/j.gastro.2018.03.063
– reference: 31614122 - Gastroenterology. 2019 Dec;157(6):1684-1686
SSID ssj0015275
Score 2.4734776
Snippet There is a need for safe and effective IBS treatments that provide immediate and sustained improvement of IBS symptoms, particularly among more severe...
BACKGROUND:There is a need for safe and effective IBS treatments that provide immediate and sustained improvement of IBS symptoms, particularly among more...
SourceID pubmedcentral
proquest
pubmed
crossref
SourceType Open Access Repository
Aggregation Database
Index Database
Enrichment Source
StartPage 330
SubjectTerms Abdomen
Adult
Clinical trials
Cognition & reasoning
Cognitive behavioral therapy
Cognitive Behavioral Therapy - methods
Design
Education
Exercise
Female
Follow-Up Studies
Humans
Irritable bowel syndrome
Irritable Bowel Syndrome - therapy
Male
Middle Aged
Pain
Patients
Psychotherapy
Treatment Outcome
Title Durability and Decay of Treatment Benefit of Cognitive Behavioral Therapy for Irritable Bowel Syndrome: 12-Month Follow-Up
URI https://www.ncbi.nlm.nih.gov/pubmed/30429592
https://www.proquest.com/docview/3243121924
https://www.proquest.com/docview/2133823730
https://pubmed.ncbi.nlm.nih.gov/PMC6737527
Volume 114
WOSCitedRecordID wos000463158000024&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
journalDatabaseRights – providerCode: PRVPQU
  databaseName: Health & Medical Collection
  customDbUrl:
  eissn: 1572-0241
  dateEnd: 20241207
  omitProxy: false
  ssIdentifier: ssj0015275
  issn: 0002-9270
  databaseCode: 7X7
  dateStart: 20190101
  isFulltext: true
  titleUrlDefault: https://search.proquest.com/healthcomplete
  providerName: ProQuest
– providerCode: PRVPQU
  databaseName: ProQuest Central
  customDbUrl:
  eissn: 1572-0241
  dateEnd: 20241207
  omitProxy: false
  ssIdentifier: ssj0015275
  issn: 0002-9270
  databaseCode: BENPR
  dateStart: 20190101
  isFulltext: true
  titleUrlDefault: https://www.proquest.com/central
  providerName: ProQuest
link http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Lb9QwEB7RLUJceJRHA6UyEiekqImT2DEXxLZdgQSrCrZob1Hs2OpKq2TZZPvg1zNOnMCC1AuXHGJHiTPjz-OZ8TcAb1BnFc1Dmz0V2hJmTPsiNsrnidFFYIwoWofb9898Ok3nc3HmHG61S6vsMbEF6qJS1kd-hAt_FFK7XXi_-uHbqlE2uupKaOzArmUqi0ewOz6dnn0d4ggJ5UlvAAvKh7hmlB7VCN_2dHJoj5gJ5l9vr0z_mJt_Z03-sQxNHv7vAB7BA2eAkg-dxjyGO7rcs7WbXZ7HHtz74sLtT-DnyWbd8XjfkLwsyIlW-Q2pDJn16elkjFhpFo29edxnIpHxcPafzDrWAoK2Mfm0tp4IucQO1ZVekm-OLeEdCamP4NJckAmqZXXln6-ewvnkdHb80XfFGnwVi6hBoIq4pgzFzmOJVphQOsmTJFUsKApEERFJ3EzKQobUJExraZiUURrEWsow0Sx6BqOyKvU-kEBxxCHDQ81YXOhYyJgrkQeSKbQWufQg6AWVKcdkbgtqLLM2oh6lWSfbDGWbWdlm1x68HR5ZdTQet3U-6CWYuRldZ7_F58HroRnnog2w5KWuNnVG7Yaf4p8IPHjeKcvwNus2EomgHvAtNRo6WJ7v7ZZycdHyfdtSQqjIL27_rJdwH4050WWUH8CoWW_0K7irLptFvT6EHT7n7TU9dJPkF8hJF_E
linkProvider ProQuest
linkToHtml http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1Jb9NAFH4qBQEXlrLUUGCQ4IJk1R4vk0FCiDZEjZpGSKQoN9czHquRIjuNE9Lwo_iNvOcNAlJvPXD1jBeNv7fON-8BvEHMah67xJ5yqYVZaGzpp9oWQWoSJ01lUibcvg3EcNgZj-WXLfjZnIUhWmWjE0tFneSacuT7aPg9l1O48HF2YVPXKNpdbVpoVLA4NusVhmzFh34X_-9bznufR4dHdt1VwNa-9BYoUZ4wPMTvE75Cd0FqE8RB0NGhkyQId-kpjHpUolyeBqExKg2V8jqOb5RyAxN6-NwbcBP1uCAKmRi3AR51iA0ad1ty0e6iep39Ao0FnYV26UCbDO3LTTv4j3P7N0fzD6PXu_-_LdcDuFe71-xTJQ8PYctkO9SZumax7MDtk5pM8Ah-dJfzqkr5msVZwrpGx2uWp2zUkO_ZAVqCdLKgi4cNz4odtJUN2KiqycDQ82f9OeVZ1BQn5CszZV_rWhDvmcttVJ2Lc9ZDoctX9unsMZxeyyo8ge0sz8wuMEcL1LKpcE0Y-onxpfKFlrGjQo2-sFAWOA0wIl3Xaad2IdOo5At4najCUoRYighL0aUF79pbZlWRkqsm7zWIiWp9VUS_4WLB63YYNQ1tH8WZyZdFxCmdwXElHAueVuBs30ZJMRlIboHYgG07gaqYb45kk_Oymjk1SkLBeXb1Z72CO0ejk0E06A-Pn8NddFtlxZ3fg-3FfGlewC39fTEp5i9LkWRwdt2g_gV9WHFK
linkToPdf http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1bb9MwFD4aHZp44TJugQFGghekqIlzcYyEEF1XUW1UFXRob17sOFqlKilNSld-Gr-O4-YCBWlve-A1di5yvnPxOZ_PAXiFmFU0dg17yjUtzEJtcz9VNgtSnThpypNNwO3rCRuNorMzPt6Bn81ZGEOrbHTiRlEnuTIx8i4afs-lZrvQTWtaxLg_eD__ZpsOUibT2rTTqCByrNcr3L4V74Z9_NevKR0cTQ4_2nWHAVv53CtRujymaYjfynyJrgNXOoiDIFKhkyQIfe5J3AHJRLo0DUKtZRpK6UWOr6V0Ax16-NwbsMvQyQg6sNs7Go0_tzmMgLKgcb45ZW1O1Yu6BZoOczLaNcfbeGhfblvFf1zdvxmbf5jAwZ3_efHuwu3a8SYfKkm5Bzs62zc9q2t-yz7sfappBvfhR3-5qOqXr0mcJaSvVbwmeUomDS2f9NBGpNPSXDxsGFik19Y8IJOqWgPBPQEZLkwERs5wQr7SM_KlrhLxlrjURqVaXpABimO-sk_nD-D0WlbhIXSyPNOPgTiKof5NmavD0E-0z6XPFI8dGSr0kpm0wGlAIlRdwd00EpmJDZPAi0SFK4G4EgZX4tKCN-0t86p8yVWTDxr0iFqTFeI3dCx42Q6jDjKJpTjT-bIQ1AQ6KK6EY8GjCqjt20y4jAecWsC2INxOMPXNt0ey6cWmzrlpoYRC9OTqz3oBe4hlcTIcHT-FW-jP8opUfwCdcrHUz-Cm-l5Oi8XzWj4JnF83qn8BDmh7ag
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Durability+and+Decay+of+Treatment+Benefit+of+Cognitive+Behavioral+Therapy+for+Irritable+Bowel+Syndrome%3A+12-Month+Follow-Up&rft.jtitle=The+American+journal+of+gastroenterology&rft.au=Lackner%2C+Jeffrey+M.&rft.au=Jaccard%2C+James&rft.au=Radziwon%2C+Christopher+D.&rft.au=Firth%2C+Rebecca+S.&rft.date=2019-02-01&rft.issn=0002-9270&rft.eissn=1572-0241&rft.volume=114&rft.issue=2&rft.spage=330&rft.epage=338&rft_id=info:doi/10.1038%2Fs41395-018-0396-x&rft_id=info%3Apmid%2F30429592&rft.externalDocID=PMC6737527
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0002-9270&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0002-9270&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0002-9270&client=summon